Additionally, the 36-month beta value for NAMS is 0.01. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NAMS is 39.19M and currently, short sellers hold a 4.31% ratio of that float. The average trading volume of NAMS on August 29, 2024 was 326.25K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NAMS) stock’s latest price update
NewAmsterdam Pharma Company NV (NASDAQ: NAMS)’s stock price has gone rise by 0.67 in comparison to its previous close of 16.31, however, the company has experienced a -0.67% decrease in its stock price over the last five trading days. benzinga.com reported 2024-08-28 that Needham has initiated coverage on NewAmsterdam Pharma Company N.V NAMS, a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.
NAMS’s Market Performance
NewAmsterdam Pharma Company NV (NAMS) has seen a -0.67% fall in stock performance for the week, with a -4.09% decline in the past month and a -11.34% plunge in the past quarter. The volatility ratio for the week is 7.78%, and the volatility levels for the past 30 days are at 6.21% for NAMS. The simple moving average for the last 20 days is -1.00% for NAMS’s stock, with a simple moving average of -8.79% for the last 200 days.
Analysts’ Opinion of NAMS
Scotiabank, on the other hand, stated in their research note that they expect to see NAMS reach a price target of $35. The rating they have provided for NAMS stocks is “Sector Outperform” according to the report published on March 14th, 2024.
Guggenheim gave a rating of “Buy” to NAMS, setting the target price at $30 in the report published on January 18th of the current year.
NAMS Trading at -9.26% from the 50-Day Moving Average
After a stumble in the market that brought NAMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.69% of loss for the given period.
Volatility was left at 6.21%, however, over the last 30 days, the volatility rate increased by 7.78%, as shares sank -5.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.56% lower at present.
During the last 5 trading sessions, NAMS fell by -1.21%, which changed the moving average for the period of 200-days by +63.46% in comparison to the 20-day moving average, which settled at $16.54. In addition, NewAmsterdam Pharma Company NV saw 47.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAMS starting from Davidson Michael H., who purchase 5,000 shares at the price of $16.27 back on Aug 20 ’24. After this action, Davidson Michael H. now owns 209,784 shares of NewAmsterdam Pharma Company NV, valued at $81,350 using the latest closing price.
Davidson Michael H., the Chief Executive Officer of NewAmsterdam Pharma Company NV, purchase 5,000 shares at $17.26 during a trade that took place back on Jun 20 ’24, which means that Davidson Michael H. is holding 204,784 shares at $86,308 based on the most recent closing price.
Stock Fundamentals for NAMS
Current profitability levels for the company are sitting at:
- -13.63 for the present operating margin
- 1.0 for the gross margin
The net margin for NewAmsterdam Pharma Company NV stands at -12.46. The total capital return value is set at -0.48.
Based on NewAmsterdam Pharma Company NV (NAMS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -218.71.
Currently, EBITDA for the company is -171.63 million with net debt to EBITDA at 2.31. When we switch over and look at the enterprise to sales, we see a ratio of 74.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.83.
Conclusion
In conclusion, NewAmsterdam Pharma Company NV (NAMS) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
